Chronic Disease Control

Value of plasma C4d combined with complements C3 and C4 in the diagnosis and prognosis prediction of systemic lupus erythematosus combined with lupus nephritis

  • Yanling LIU ,
  • Huimin ZHANG ,
  • Jingjing YUE ,
  • Xiaojing CHEN
Expand
  • Department of Rheumatology and Immunology,Affiliated Hospital of Chengde Medical University,Chengde 067000,Hebei,China

Received date: 2026-03-12

  Online published: 2026-06-30

Abstract

Objective To observe the change characteristics of C4d, complements C3 and C4 in patients with systemic lupus erythematosus and lupus nephritis (SLE-LN), and to analyze their clinical value in the early diagnosis of SLE-LN, the evaluation of disease severity, and the prognosis prediction. Methods A total of 98 patients with systemic lupus erythematosus (SLE) who received treatment at the Affiliated Hospital of Chengde Medical University were recruited as the research subjects from January 2024 to January 2025. Based on the occurrence of lupus nephritis (LN), they were divided into the SLE-LN group (38 cases) and the simple SLE group (60 cases). The levels of plasma C4d, complements C3, and C4 were measured using the enzyme-linked immunosorbent assay (ELISA). The 24-hour urine protein, serum creatinine (Scr), blood urea nitrogen (BUN), and uric acid (UA) were determined, and the estimated glomerular filtration rate (eGFR) was calculated. The correlation between C4d, C3, C4 and 24-hour urine protein, as well as renal function, was analyzed by Pearson correlation analysis. All 98 SLE patients were followed up for 12 months. According to the changes in renal function, they were divided into the poor prognosis group (with deteriorated renal function, 29 cases) and the good prognosis group (with stable renal function, 66 cases). The predictive value of C4d, C3, and C4 for the prognosis of SLE was analyzed by receiver operating characteristic (ROC) curves analysis. Results The plasma C4d level in the SLE-LN group was significantly higher than that in the simple SLE group, whereas the C3 and C4 levels were significantly lower than those in the simple SLE group (P < 0.05). The 24 - hour urine protein, Scr, BUN, and uric acid (UA) levels in the SLE-LN group were significantly higher than those in the simple SLE group, while the eGFR was significantly lower than that in the simple SLE group (P < 0.05). Pearson correlation analysis indicated that the C4d level was significantly positively correlated with the 24-hour urine protein, Scr, BUN, and UA levels (P < 0.05), and significantly negatively correlated with the eGFR (P < 0.05). The C3 and C4 levels were significantly negatively correlated with the 24 - hour urine protein, Scr, BUN, and UA levels (P < 0.05), and significantly positively correlated with the eGFR (P < 0.05). The plasma C4d level in the poor prognosis group was significantly higher than that in the good prognosis group, while the C3 and C4 levels were significantly lower than those in the good prognosis group (P < 0.05). Receiver operating characteristic (ROC) curve analysis showed that the area under the curve (AUC), sensitivity, and specificity of the combined detection were 0.868, 79.31%, and 86.36% respectively, which had the highest predictive efficiency for the prognosis of SLE patients. Conclusions Compared with patients with simple SLE, the level of plasma C4d is higher, while the levels of complements C3 and C4 are lower in patients with SLE-LN. All three of these indexes are significantly correlated with 24-hour urine protein and renal function. The combined detection of plasma C4d, C3, and C4 has a higher predictive efficiency for the prognosis of SLE patients.

Cite this article

Yanling LIU , Huimin ZHANG , Jingjing YUE , Xiaojing CHEN . Value of plasma C4d combined with complements C3 and C4 in the diagnosis and prognosis prediction of systemic lupus erythematosus combined with lupus nephritis[J]. The Journal of Practical Medicine, 2026 , 42(12) : 2194 -2199 . DOI: 10.3969/j.issn.1006-5725.2026.12.014

References

[1] ELIA A, ZUCCHI D, SILVAGNI E, et al. Systemic lupus erythematosus: One year in review 2025[J]. Clin Exp Rheumatol, 2025,43(3):397-406. doi: 10.55563/clinexprheumatol/m0pi1k .
[2] MORAND E F, FERNANDEZ-RUIZ R, BLAZER A, et al. Advances in the management of systemic lupus erythematosus[J]. BMJ, 2023,383(1):e073980. doi: 10.1136/bmj-2022-073980 .
[3] DAI X, FAN Y, ZHAO X. Systemic lupus erythematosus: Updated insights on the pathogenesis, diagnosis, prevention and therapeutics[J]. Signal Transduct Target Ther, 2025,10(1):102. doi: 10.1038/s41392-025-02168-0 .
[4] WANG W, HE S, ZHANG W, et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: A phase 1 open-label clinical trial[J]. Ann Rheum Dis, 2024,83(10):1304-1314. doi: 10.1136/ard-2024-225785 .
[5] 田新平,李梦涛,曾小峰. 我国系统性红斑狼疮的诊治现状与未来发展方向:来自中国系统性红斑狼疮发展报告2020年年度报告[J]. 中华内科杂志,2022,61(6):611-616. doi:10.3760/cma.j.cn112138-20220324-00206 .
[6] CHANG K, NA W, LIU C, et al. Peripheral CD4+CD8+ double positive T cells: A potential marker to evaluate renal impairment susceptibility during systemic lupus erythematosus[J]. J Biomed Res, 2022,37(1):59-68. doi: 10.7555/JBR.36.20220094 . Online ahead of print.
[7] WANG S S Y, TANG H, LOE M W C, et al. Complements and Their Role in Systemic Disorders[J]. Cureus, 2024,16(1):e52991. doi: 10.7759/cureus.52991. eCollection 2024 Jan .
[8] SHATRI H, PURNAMANDALA, HIDAYAT R, et al. The correlation of anxiety and depression with C3 and C4 Levels and systemic lupus erythematosus activity[J]. BMC Psychiatry, 2023, 23(1):785. doi: 10.1186/s12888-023-05285-8 .
[9] 傅嘉莹,田耘,李江徽,等.补体C4d与IgA肾病研究进展[J].中华实用诊断与治疗杂志, 2025, 39(2):189-192. doi:10.13507/j.issn.1674-3474.2025.02.017 .
[10] QIN S, WANG X, WANG J, et al. Complement C4d as a biomarker for systemic lupus erythematosus and lupus nephritis[J]. Lupus, 2024,33(2):111-120. doi: 10.1177/09612033231226351 .
[11] ZAGOREC N, HORVATI? I, KASUMOVI? D, et al. C4d Is an Independent Predictor of the Kidney Failure in Primary IgA Nephropathy[J]. J Clin Med, 2024, 13(17):5338. doi: 10.3390/jcm13175338 .
[12] 国家皮肤与免疫疾病临床医学研究中心,中国系统性红斑狼疮研究协作组,中华医学会风湿病学分会. 中国系统性红斑狼疮诊疗指南(2025版)[J]. 中华医学杂志,2025,105(23):1879-1906. doi:10.12290/xhyxzz.2025-0726 .
[13] 中华医学会儿科学分会肾脏学组. 狼疮性肾炎诊治循证指南(2016)[J]. 中华儿科杂志,2018,56(2):88-94. doi:10.3760/cma.j.issn.0578-1310.2018.02.003 .
[14] MA J, ZHANG L, YAN M, et al. Value of SLE-DAS in assessing disease activity in patients with systemic lupus erythematosus: A single-centre retrospective study[J]. Lupus Sci Med, 2024,11(1):e001196. doi: 10.1136/lupus-2024-001196 .
[15] YOO E J, OH K H, PIAO H, et al. Macrophage transcription factor TonEBP promotes systemic lupus erythematosus and kidney injury via damage-induced signaling pathways[J]. Kidney Int, 2023, 104(1):163-180. doi: 10.1016/j.kint.2023.03.030 .
[16] SAMMARITANO L R, ASKANASE A, BERMAS B L, et al. 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis[J]. Arthritis Rheumatol, 2025,77(9):1115-1135. doi: 10.1002/ art.43212 .
[17] 王乾宇,陈美彤,郭兆安. NLRP3炎性小体在狼疮性肾炎发病机制中的作用及其研究进展[J]. 细胞与分子免疫学杂志,2025,41(10):929-936. doi:10.13423/j.cnki.cjcmi.009996 .
[18] TSAI C Y, WU T H, OU S M, et al. The Pathogenesis, Potential Biomarkers and Novel Therapeutic Strategies for Tubulointerstitial Nephritis in Systemic Lupus Erythematosus-A Narrative Review[J]. Int J Mol Sci, 2025,26(22):10903. doi: 10.3390/ijms262210903 .
[19] 王佳丽,崔安凤,韩伟霞,等. 狼疮性肾炎中相关尿液生物标志物的研究进展[J]. 中国免疫学杂志, 2024, 40(10):2189-2193. doi:10.3969/j.issn.1000-484X.2024.10.029 .
[20] 钱香,杨平. 活动期系统性红斑狼疮患者血清补体C3,C4,C1q水平变化及其诊断和鉴别诊断效能[J]. 山东医药, 2024, 64(36):36-39. doi:10.3969/j.issn.1002-266X.2024.36.007 .
[21] ZICKERT A, GR?NWALL C, JUTO A, et al. Plasma C4d levels correlate with treatment response and renal activity in proliferative lupus nephritis[J]. Rheumatology (Oxford), 2025, 64(8):4825-4833. doi: 10.1093/rheumatology/keaf160 .
[22] SAADATI N, MIRI M. Evaluation of serum C4d levels in patients with systemic lupus erythematosus and its relation to lupus nephritis[J]. Caspian J Intern Med, 2023,14(2):231-236. doi: 10.22088/cjim.14.2.231 .
[23] 蒋道芳,马晓燕,王奕,等. 特发性膜性肾病患者血清补体C3水平与血压及估算肾小球滤过率的相关性分析[J]. 中华肾脏病杂志, 2024, 40(6):475-480. doi:10.3760/cma.j.cn441217-20231207-01213 .
[24] JIANG X, LAN L, ZHOU Q, et al. Characteristics and renal survival of patients with lupus nephritis with glomerular immunoglobulin G4 deposition: A single-centre retrospective analysis[J]. Lupus Sci Med, 2022,9(1):e000690. doi: 10.1136/lupus-2022-000690 .
[25] TEYMUR A, TANG C, NAZIR F, et al. Urinary V-Set Ig Domain-Containing Protein 4 and Immune Complexes for Tracking Lupus Nephritis and Renal Pathology[J]. ACR Open Rheumatol, 2025, 7(5):e70044. doi: 10.1002/acr2.70044 .
[26] WANG S, WU M, CHIRIBOGA L, et al. Membrane attack complex (MAC) deposition in renal tubules is associated with interstitial fibrosis and tubular atrophy: A pilot study[J]. Lupus Sci Med, 2022,9(1):e000576. doi: 10.1136/lupus-2021-000576 .
Outlines

/